Form 8-K - Current report:
SEC Accession No. 0001437749-23-014365
Filing Date
2023-05-15
Accepted
2023-05-15 09:10:17
Documents
14
Period of Report
2023-05-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K atos20230508_8k.htm   iXBRL 8-K 27174
2 EXHIBIT 99.1 ex_518473.htm EX-99.1 97337
  Complete submission text file 0001437749-23-014365.txt   267006

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA atos-20230515.xsd EX-101.SCH 3602
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE atos-20230515_def.xml EX-101.DEF 11533
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE atos-20230515_lab.xml EX-101.LAB 15415
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atos-20230515_pre.xml EX-101.PRE 11689
8 EXTRACTED XBRL INSTANCE DOCUMENT atos20230508_8k_htm.xml XML 2556
Mailing Address 107 SPRING STREET SEATTLE WA 98104
Business Address 107 SPRING STREET SEATTLE WA 98104 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

IRS No.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35610 | Film No.: 23918887
SIC: 2834 Pharmaceutical Preparations